Effect of Riocigaut on Migraine Attack Induction and Cerebral Vasodilation in Migraine Patients.

Sponsor

Danish Headache Center (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT05750446

Collaborator

(none)

Enrollment

Location

Arms

Anticipated Duration (Months)

1.5

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This double-blind, randomized, placebo-controlled cross-over clinical trial aims to investigate the effects of riocigaut on migraine inducing properties and cerebral arteries in patients with migraine.

Condition or Disease	Intervention/Treatment	Phase
Migraine Without Aura	Drug: Riociguat (BAY 63-2521) Other: Placebo	N/A

Detailed Description

The investigators believe that activation of sGC could play a role in migraine pathophysiology and propose that stimulation with riociguat causes migraine attacks alongside cranial arterial dilation in patients with migraine.

Twenty-one patients with migraine will participate at a screening visit and, if eligible, on two separate study days, where participants, in a randomized cross-over fashion, will ingest either riociguat (active comparator arm) or placebo (placebo comparator arm), serving as their own controls. On the two separate study days the investigators will measure change in diameter of superficial temporal artery and middle cerebral artery blood flow velocity, heart rate, blood pressure and register possible headache/migraine including associated symptoms until 6 hours after intake of riociguat or placebo. At home participants are expected to fill out a headache diary until 12 hours from intake of riociguat or placebo.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

21 participants

Allocation:

Randomized

Intervention Model:

Crossover Assignment

Masking:

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Primary Purpose:

Other

Official Title:

Riociguat (BAY 63-2521), a Stimulator of Soluble Guanylate Cyclase (sGC) - Migraine Induction and Cerebral Vasodilation in Migraine Patients.

Anticipated Study Start Date :

Apr 1, 2023

Anticipated Primary Completion Date :

May 31, 2024

Anticipated Study Completion Date :

May 31, 2024

Arms and Interventions

Arm	Intervention/Treatment
Other: Riociguat / Placebo Riociguat or Placebo as oral capsule in randomized order	Drug: Riociguat (BAY 63-2521) A selective stimulator of soluble guanylate cyclase (sGC) Other Names: Adempas Other: Placebo Placebo
Other: Placebo / Riociguat Riociguat or Placebo as oral capsule in randomized order	Drug: Riociguat (BAY 63-2521) A selective stimulator of soluble guanylate cyclase (sGC) Other Names: Adempas Other: Placebo Placebo

Arm

Intervention/Treatment

Other: Riociguat / Placebo

Riociguat or Placebo as oral capsule in randomized order

Drug: Riociguat (BAY 63-2521)

A selective stimulator of soluble guanylate cyclase (sGC)

Other Names:

Adempas

Other: Placebo

Placebo

Other: Placebo / Riociguat

Riociguat or Placebo as oral capsule in randomized order

Drug: Riociguat (BAY 63-2521)

A selective stimulator of soluble guanylate cyclase (sGC)

Other Names:

Adempas

Other: Placebo

Placebo

Outcome Measures

Primary Outcome Measures

Difference in incidence of migraine attacks between riociguat and placebo during a 12-hour observational period after ingestion. [0-12 hours]
Data will be collected with a questionnaire.

Secondary Outcome Measures

Difference in superficial temporal artery (STA) diameter between baseline and 90 minutes after receiving riociguat compared to placebo. [0-90 minutes]
Measured by high resolution ultrasonography.
Difference in superficial temporal artery (STA) diameter between baseline and onset of migraine attack after receiving riociguat (maximum 6 hours after receiving riociguat) compared to placebo. [0-6 hours (max)]
STA diameter will be measured by high resolution ultrasonography. Data on migraine attack will be collected with a questionnaire.
Difference in middle cerebral artery (MCA) blood flow velocity between baseline and 90 minutes after receiving riociguat compared to placebo. [0-90 minutes]
Measured by transcranial doppler.
Difference in middle cerebral artery (MCA) blood flow velocity between baseline and onset of migraine attack after receiving riociguat (maximum 6 hours after receiving riociguat) compared to placebo. [0-6 hours (max)]
MCA blood flow velocity will be measured by transcranial doppler. Data on migraine attack will be collected with a questionnaire.
Difference in incidence of headache (>0 on Numeric Rating Scale (NRS) from 0 to 10, where 0="no pain" versus 1-10="pain") between riociguat and placebo during a 12-hour observational period after ingestion. [0-12 hours]
Data will be collected with a questionnaire.
Difference in severity of headache rated on 11-point NRS from 0 ("no pain") to 10 ("worst pain imaginable") between riociguat and placebo during a 12-hour observational period after ingestion. [0-12 hours]
Data will be collected with a questionnaire.

Other Outcome Measures

Difference in use of rescue medication to treat headache and migraine attack between riociguat and placebo during a 12-hour observational period after ingestion. [0-12 hours]
Exploratory outcome. Data will be collected with a questionnaire.
Difference in superficial temporal artery (STA) diameter in the time-course from baseline until 6 hours after receiving riociguat compared to placebo. [0-6 hours]
Exploratory outcome. Measured by high resolution ultrasonography.
Difference in middle cerebral artery (MCA) blood flow velocity in the time-course from baseline until 6 hours after receiving riociguat compared to placebo. [0-6 hours]
Exploratory outcome. Measured by transcranial doppler.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 45 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

A history of migraine without aura for ≥ 12 months according to the classification criteria of the International Classification of Headache Disorders 3rd Edition (ICHD-3) criteria.
Ability to provide written informed consent and receive participant privacy and rights information prior to initiation of any study-specific activities.
Male or female participants aged 18-45 years at screening.
No migraine preventive treatment at screening or during study conduction.
Non-smokers

Exclusion Criteria:

Any current or previous history of other primary or secondary headache disorder(s) apart from tension type headache ≤ 5 days per month.
Lack of ability to differentiate migraine from other headaches
Headache within 24 hours before any study related procedures (Provocation Day 1 and Provocation Day 2) - Subjects are however allowed to be re-booked for provocation days according to allowed timelines.
Any daily medication apart from contraceptives.
Use of any antihypertensive, nitrates or nitric oxide donors or phosphodiesterase inhibitors, CYP3A4 and P-glycoprotein inhibitors, HIV-proteaseinhibitors, ciclosporin A or CYP1A1-inhibitors, antacida and acid-neutreulizing agents (such as aluminium-/magnesiumhydroxid), CYP3A4-inductors (such as bosentan, phenytoin, carbamazepin, phenobarbital and herbal remedies with perikon).
Intake of any pro necessitate medication later than 4 times plasma half-life for the specific drug before study start.
Women of child-bearing potential not currently using safe contraceptives. Women of child-bearing potential does not include hysterectomized women and women who have been in menopause for at least 2 years. Safe contraceptives include either IUD, birth control pills, surgical sterilization of the woman, depositary gestagen, barrier prevention or sexual abstinence.
Pregnant or breastfeeding women
Positive pregnancy urine screening on screening day or provocation days.
A medical history or clinical signs of
Hypertension (systolic blood pressure >150mmHg and/or diastolic blood pressure

100mmHg)

Hypotension (systolic blood pressure <100mmHg and/or diastolic blood pressure <50mmHg)
Electrocardiogram (ECG) with any clinically significant abnormalities at screening determined by the investigator, including but not limited to, prolonged PQ or QTc interval, signs of arrythmias, ischemia or left/right ventricle dysfunction/hypertrophy.
A medical history or clinical signs of pulmo-/cardiovascular disease including cerebrovascular disease.
A family history of severe cardiac disease.
A medical history or clinical signs of clinically significant psychiatric illness per investigator opinion.
The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior.
A medical history or clinical signs of substance or alcohol abuse
A medical history or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the site investigator, would pose a risk to subject safety or interfere with study evaluation, procedures or completion.
Any history of hypersensitivity to riociguat.
Subjects who do not want information about crucial pathological findings during the study
Subject likely to not be available to complete all protocol-required study visits or procedures, and/or comply with all required study procedures to the best of the subject and study investigator's knowledge.